vs
湘南美容医疗集团（SBC）与Oncology Institute, Inc.（TOI）财务数据对比。点击上方公司名可切换其他公司
Oncology Institute, Inc.的季度营收约是湘南美容医疗集团的3.6倍（$142.0M vs $39.6M）。湘南美容医疗集团净利率更高（35.9% vs -5.3%，领先41.2%）。Oncology Institute, Inc.同比增速更快（41.6% vs -10.9%）。湘南美容医疗集团自由现金流更多（$51.2M vs $2.2M）。过去两年Oncology Institute, Inc.的营收复合增速更高（22.5% vs -15.0%）
湘南美容医疗集团是总部位于日本的知名医疗服务提供商，核心业务覆盖美容整形、皮肤科诊疗、抗衰老健康护理等领域，在日本各地运营大量连锁诊所，同时服务本地居民及赴日就医的国际游客。
肿瘤研究所股份有限公司是一家专注于肿瘤诊疗领域的专业医疗企业，提供循证抗癌治疗方案、临床试验参与通道及配套支持护理服务，主要面向美国境内各类癌症患者，协同医疗从业者优化诊疗效果。
SBC vs TOI — 直观对比
营收规模更大
TOI
是对方的3.6倍
$39.6M
营收增速更快
TOI
高出52.5%
-10.9%
净利率更高
SBC
高出41.2%
-5.3%
自由现金流更多
SBC
多$49.0M
$2.2M
两年增速更快
TOI
近两年复合增速
-15.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $39.6M | $142.0M |
| 净利润 | $14.2M | $-7.5M |
| 毛利率 | 73.1% | — |
| 营业利润率 | 32.5% | -4.9% |
| 净利率 | 35.9% | -5.3% |
| 营收同比 | -10.9% | 41.6% |
| 净利润同比 | 117.2% | 43.0% |
| 每股收益（稀释后） | $0.15 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SBCTOI
| Q4 25 | $39.6M | $142.0M | ||
| Q3 25 | $43.4M | $136.6M | ||
| Q2 25 | $43.4M | $119.8M | ||
| Q1 25 | $47.3M | $104.4M | ||
| Q4 24 | $44.4M | $100.3M | ||
| Q3 24 | $53.1M | $99.9M | ||
| Q2 24 | $53.1M | $98.6M | ||
| Q1 24 | $54.8M | $94.7M |
净利润SBCTOI
| Q4 25 | $14.2M | $-7.5M | ||
| Q3 25 | $12.8M | $-16.5M | ||
| Q2 25 | $2.5M | $-17.0M | ||
| Q1 25 | $21.5M | $-19.6M | ||
| Q4 24 | $6.5M | $-13.2M | ||
| Q3 24 | $2.8M | $-16.1M | ||
| Q2 24 | $18.5M | $-15.5M | ||
| Q1 24 | $18.8M | $-19.9M |
毛利率SBCTOI
| Q4 25 | 73.1% | — | ||
| Q3 25 | 70.6% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 76.3% | — | ||
| Q3 24 | 81.5% | — | ||
| Q2 24 | 74.2% | — | ||
| Q1 24 | 72.1% | — |
营业利润率SBCTOI
| Q4 25 | 32.5% | -4.9% | ||
| Q3 25 | 36.6% | -5.9% | ||
| Q2 25 | 33.6% | -9.4% | ||
| Q1 25 | 51.1% | -9.5% | ||
| Q4 24 | 10.6% | -11.9% | ||
| Q3 24 | 26.1% | -13.9% | ||
| Q2 24 | 51.4% | -16.6% | ||
| Q1 24 | 44.6% | -19.0% |
净利率SBCTOI
| Q4 25 | 35.9% | -5.3% | ||
| Q3 25 | 29.6% | -12.1% | ||
| Q2 25 | 5.7% | -14.2% | ||
| Q1 25 | 45.4% | -18.8% | ||
| Q4 24 | 14.7% | -13.1% | ||
| Q3 24 | 5.3% | -16.1% | ||
| Q2 24 | 34.8% | -15.7% | ||
| Q1 24 | 34.2% | -21.0% |
每股收益（稀释后）SBCTOI
| Q4 25 | $0.15 | $-0.04 | ||
| Q3 25 | $0.12 | $-0.14 | ||
| Q2 25 | $0.02 | $-0.15 | ||
| Q1 25 | $0.21 | $-0.21 | ||
| Q4 24 | $0.05 | $-0.14 | ||
| Q3 24 | $0.03 | $-0.18 | ||
| Q2 24 | $0.20 | $-0.17 | ||
| Q1 24 | $0.20 | $-0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $164.1M | — |
| 总债务越低越好 | $42.8M | — |
| 股东权益账面价值 | $248.3M | $-15.7M |
| 总资产 | $380.4M | $164.7M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资SBCTOI
| Q4 25 | $164.1M | — | ||
| Q3 25 | $127.4M | — | ||
| Q2 25 | $152.7M | — | ||
| Q1 25 | $132.1M | — | ||
| Q4 24 | $125.0M | — | ||
| Q3 24 | $137.4M | — | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $29.8M |
总债务SBCTOI
| Q4 25 | $42.8M | — | ||
| Q3 25 | $21.1M | — | ||
| Q2 25 | $7.1M | — | ||
| Q1 25 | $6.9M | — | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $823.2K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益SBCTOI
| Q4 25 | $248.3M | $-15.7M | ||
| Q3 25 | $248.0M | $-12.3M | ||
| Q2 25 | $244.6M | $-9.0M | ||
| Q1 25 | $226.4M | $5.1M | ||
| Q4 24 | $195.1M | $3.6M | ||
| Q3 24 | $205.0M | $15.5M | ||
| Q2 24 | $8.8M | $29.2M | ||
| Q1 24 | $9.0M | $41.3M |
总资产SBCTOI
| Q4 25 | $380.4M | $164.7M | ||
| Q3 25 | $321.4M | $163.6M | ||
| Q2 25 | $315.3M | $159.8M | ||
| Q1 25 | $284.6M | $164.0M | ||
| Q4 24 | $266.1M | $172.7M | ||
| Q3 24 | $296.5M | $179.2M | ||
| Q2 24 | $19.5M | $179.6M | ||
| Q1 24 | $19.8M | $204.5M |
负债/权益比SBCTOI
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.09× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 0.03× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $52.0M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | $51.2M | $2.2M |
| 自由现金流率自由现金流/营收 | 129.3% | 1.5% |
| 资本支出强度资本支出/营收 | 2.0% | 0.7% |
| 现金转化率经营现金流/净利润 | 3.66× | — |
| 过去12个月自由现金流最近4个季度 | $23.3M | $-27.8M |
8季度趋势，按日历期对齐
经营现金流SBCTOI
| Q4 25 | $52.0M | $3.2M | ||
| Q3 25 | $-20.9M | $-12.6M | ||
| Q2 25 | $-8.3M | $-10.2M | ||
| Q1 25 | $1.9M | $-5.0M | ||
| Q4 24 | $-7.3M | $4.2M | ||
| Q3 24 | $5.0M | $819.0K | ||
| Q2 24 | $19.2M | $-15.7M | ||
| Q1 24 | $3.7M | $-15.9M |
自由现金流SBCTOI
| Q4 25 | $51.2M | $2.2M | ||
| Q3 25 | $-20.9M | $-13.2M | ||
| Q2 25 | $-8.6M | $-11.4M | ||
| Q1 25 | $1.7M | $-5.3M | ||
| Q4 24 | $-7.9M | $2.4M | ||
| Q3 24 | $4.6M | $417.0K | ||
| Q2 24 | $18.3M | $-17.5M | ||
| Q1 24 | $3.0M | $-16.5M |
自由现金流率SBCTOI
| Q4 25 | 129.3% | 1.5% | ||
| Q3 25 | -48.3% | -9.7% | ||
| Q2 25 | -19.9% | -9.5% | ||
| Q1 25 | 3.5% | -5.1% | ||
| Q4 24 | -17.8% | 2.4% | ||
| Q3 24 | 8.7% | 0.4% | ||
| Q2 24 | 34.5% | -17.7% | ||
| Q1 24 | 5.4% | -17.4% |
资本支出强度SBCTOI
| Q4 25 | 2.0% | 0.7% | ||
| Q3 25 | 0.1% | 0.4% | ||
| Q2 25 | 0.7% | 1.0% | ||
| Q1 25 | 0.5% | 0.3% | ||
| Q4 24 | 1.3% | 1.8% | ||
| Q3 24 | 0.8% | 0.4% | ||
| Q2 24 | 1.6% | 1.9% | ||
| Q1 24 | 1.3% | 0.6% |
现金转化率SBCTOI
| Q4 25 | 3.66× | — | ||
| Q3 25 | -1.63× | — | ||
| Q2 25 | -3.39× | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | -1.12× | — | ||
| Q3 24 | 1.77× | — | ||
| Q2 24 | 1.04× | — | ||
| Q1 24 | 0.20× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SBC
| Franchising | $10.3M | 26% |
| Medical Corporation Shobikai | $8.1M | 21% |
| Medical Corporation Nasukai | $7.2M | 18% |
| Management Services | $6.3M | 16% |
| Rental Services | $4.3M | 11% |
| Medical Corporation Association Furinkai | $3.0M | 8% |
| Japan Medical And Beauty Inc | $656.5K | 2% |
TOI
| Other | $82.1M | 58% |
| Fee For Service | $36.3M | 26% |
| Capitated Revenue | $23.6M | 17% |
